Christopher Missling
Christopher U. Missling, PhD is President and CEO of Anavex Life Sciences Corp, has over 20 years of healthcare industry experience within large pharmaceutical companies and the biotech industry. Prior to joining Anavex, he served as the Chief Financial Officer of Curis and ImmunoGen. In addition, at Aventis (now Sanofi), Christopher’s work is dedicated to finding potential cures for rare diseases especially for neurodevelopmental diseases, like Rett syndrome, Fragile X, Angelman’s syndrome, infantile spasms as well as neurodegenerative diseases. Dr. Missling is working with his team to advance new potential treatments through clinical trials by involving the respective advocacy groups early on. Dr. Missling has an MS and PhD from the University of Munich in Chemistry and an MBA from Northwestern University Kellogg School of Management and WHU Otto Beisheim School of Management.
  • LinkedIn - White Circle

The Rare Advocacy Movement (RAM) is a rare disease focused community advocacy initiative focused on addressing the issues that affect the real world people of the rare disease community.  RAM serves as a community-based professional network and Center of Insight (COI) for rare disease focused stakeholders seeking authentic connections and unadulterated community insights. The RAM membership is comprised of a network of patient advocacy community expert professionals that have vowed to abide by the established Code of Conduct for Membership. As a result, every current RAM member has made a public vow to always act in the best interest of the rare disease community.